- Home
- VERA
as of 02-26-2026 3:37pm EST
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 3.4B | IPO Year: | 2021 |
| Target Price: | $76.60 | AVG Volume (30 days): | 836.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.27 | EPS Growth: | -22.22 |
| 52 Week Low/High: | $18.53 - $56.05 | Next Earning Date: | 05-27-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -12.75 | Index: | N/A |
| Free Cash Flow: | -135651000.0 | FCF Growth: | N/A |
AI-Powered VERA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vera Therapeutics Inc. (VERA)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$41.98
Shares
4,949
Total Value
$207,778.32
Owned After
114,181
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$41.98
Shares
16,925
Total Value
$710,577.51
Owned After
257,163
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$41.98
Shares
2,151
Total Value
$90,307.37
Owned After
50,947
SEC Form 4
SVP, FINANCE, CHIEF ACCT OFFCR
Avg Cost/Share
$41.98
Shares
3,117
Total Value
$130,863.82
Owned After
64,722
SEC Form 4
Chief Regulatory Officer
Avg Cost/Share
$41.98
Shares
2,187
Total Value
$91,818.79
Owned After
45,313
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$41.98
Shares
2,579
Total Value
$108,276.48
Owned After
45,727
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$41.98
Shares
1,582
Total Value
$66,418.53
Owned After
64,218
SEC Form 4
Chief Regulatory Officer
Avg Cost/Share
$50.08
Shares
10,000
Total Value
$500,767.00
Owned After
45,313
SEC Form 4
Director
Avg Cost/Share
$42.50
Shares
5,882
Total Value
$249,985.00
Owned After
5,882
SEC Form 4
Chief Regulatory Officer
Avg Cost/Share
$45.31
Shares
10,000
Total Value
$453,053.00
Owned After
45,313
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sell | $41.98 | 4,949 | $207,778.32 | 114,181 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Feb 23, 2026 | Sell | $41.98 | 16,925 | $710,577.51 | 257,163 | |
| Brenner Robert | VERA | Chief Medical Officer | Feb 23, 2026 | Sell | $41.98 | 2,151 | $90,307.37 | 50,947 | |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | Feb 23, 2026 | Sell | $41.98 | 3,117 | $130,863.82 | 64,722 | |
| Turner William D. | VERA | Chief Regulatory Officer | Feb 23, 2026 | Sell | $41.98 | 2,187 | $91,818.79 | 45,313 | |
| JOHNSON DAVID LEE | VERA | Chief Operating Officer | Feb 23, 2026 | Sell | $41.98 | 2,579 | $108,276.48 | 45,727 | |
| Skelton Laurence Matthew | VERA | Chief Commercial Officer | Feb 23, 2026 | Sell | $41.98 | 1,582 | $66,418.53 | 64,218 | |
| Turner William D. | VERA | Chief Regulatory Officer | Dec 15, 2025 | Sell | $50.08 | 10,000 | $500,767.00 | 45,313 | |
| ENRIGHT PATRICK G | VERA | Director | Dec 11, 2025 | Buy | $42.50 | 5,882 | $249,985.00 | 5,882 | |
| Turner William D. | VERA | Chief Regulatory Officer | Dec 8, 2025 | Sell | $45.31 | 10,000 | $453,053.00 | 45,313 |
Compare VERA vs Leading Stocks
See how VERA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.